Tag: InspireMD
First patient enrolled in InspireMD’s CGUARDIANS II pivotal study
InspireMD today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime carotid stent system in...
InspireMD receives IDE approval from US FDA for CGUARDIANS II pivotal...
InspireMD has announced the US Food and Drug Administration (FDA) approval of the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS II...
Vascular News’ top 10 most popular stories of August 2024
Commencement of the CALCIO trial—designed to collect real-world data on the use of intravascular lithotripsy (IVL) with the Shockwave Medical IVL system in patients...
InspireMD congratulates CREST-2 investigators on completion of trial enrolment
InspireMD today congratulated the lead investigators on the completion of enrolment in the CREST-2 clinical trials.
The CGuard embolic prevention stent system (EPS), utilising...
LINC 2024: C-GUARDIANS data represent lowest event rates in published trials...
New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent...
InspireMD presents positive 30-day follow-up results from C-GUARDIANS clinical trial
InspireMD recently presented 30-day results from the C-GUARDIANS US investigational device exemption (IDE) clinical trial evaluating its CGuard embolic prevention stent (EPS) system for...
Vascular News’ top 10 most popular stories of March 2022
A review of intraoperative adverse events in patients treated with fenestrated and branched endovascular aneurysm repair, meta-analysis findings on peripheral arterial disease symptoms in...
InspireMD announces the inclusion of its CGuard carotid stent in CREST-2...
InspireMD has announced that its CGuard embolic prevention stent system (EPS) will be included as a device option for stenting in CREST-2 (Carotid revascularisation...
SIBERIA trial: Positive one-month results for embolic prevention system
InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...
Regulatory and reimbursement approval of CGuard EPS in Australia
CGuard Embolic Prevention System (EPS) (InspireMD) has been granted regulatory approval by the Therapeutic Goods Administration (part of the Australian Government’s Department of Health)...
Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...
Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...
InspireMD announces expansion of its distribution network for CGuard EPS
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...
